Cochrane · systematic review · CD011220
Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer
Hoon, S-N, Lau, PK H, White, AM, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Breast CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
23
current version
GRADE rated
23
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 4.3%Moderate 16 · 69.6%High 6 · 26.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Capecitabine‐containing regimens compared to chemotherapy regimens without capecitabine for metastatic breast cancer
Population: people with metastatic breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival (OS)median Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine | HR 1.01 [0.98, 1.05] | 12 studies · 4325 participants | High |
OS: hormone receptor‐positivemedian Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine | HR 0.9 [0.8, 1.02] | 6 studies · 1565 participants | High |
OS: hormone receptor‐negativemedian Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine | HR 1.05 [0.91, 1.2] | 7 studies · 1408 participants | High |
Progression‐free survival (PFS)median Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine | HR 0.89 [0.83, 0.96] | 12 studies · 4325 participants | Moderate Downgraded: risk of bias |
PFS: hormone receptor‐positivemedian Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine | HR 0.77 [0.68, 0.87] | 6 studies · 1372 participants | Moderate Downgraded: risk of bias |
PFS: hormone receptor‐negativemedian Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine | HR 1.01 [0.85, 1.19] | 6 studies · 900 participants | Moderate Downgraded: risk of bias |
Objective response rate Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine | RR 0.97 [0.84, 1.11] | 12 studies · 4200 participants | Moderate Downgraded: risk of bias |
Quality of life Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine | no estimate extracted | 5 studies · 5 participants | Low Downgraded: risk of bias |
Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens for neoadjuvant treatment
Population: neoadjuvant treatment of ER‐positive vs ER‐negative breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Pathological complete response (pCR): breast and axillary nodes Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens | OR 1.12 [0.94, 1.33] | 6 studies · 3152 participants | High |
pCR: hormone receptor‐positive Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens | OR 1.22 [0.76, 1.95] | 4 studies · 964 participants | Moderate Downgraded: imprecision |
pCR: hormone receptor‐negative Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens | OR 1.28 [0.61, 2.66] | 4 studies · 646 participants | Moderate Downgraded: risk of bias, imprecision |
Disease‐free survivalmedian Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens | HR 1.02 [0.86, 1.21] | 4 studies · 2499 participants | High |
Overall survivalmedian Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens | HR 0.97 [0.77, 1.23] | 4 studies · 2499 participants | High |
Febrile neutropenia Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens | OR 1.31 [0.97, 1.77] | 4 studies · 2890 participants | Moderate Downgraded: risk of bias, imprecision |
Diarrhoea Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens | OR 1.95 [1.32, 2.89] | 3 studies · 2686 participants | Moderate Downgraded: risk of bias, imprecision |
Hand‐foot syndrome Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens | OR 6.77 [4.89, 9.38] | 5 studies · 3021 participants | Moderate Downgraded: risk of bias, imprecision |
Capecitabine‐containing regimens compared to non‐capecitabine‐containing regimens or no chemotherapy for early breast cancer
Population: people with early breast cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Disease‐free survival (DFS)median Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy | HR 0.93 [0.86, 1.01] | 8 studies · 13547 participants | Moderate Downgraded: risk of bias, indirectness |
DFS: hormone receptor‐positivemedian Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy | HR 1.03 [0.91, 1.17] | 5 studies · 5604 participants | Moderate Downgraded: risk of bias, indirectness |
DFS: hormone receptor‐negativemedian Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy | HR 0.76 [0.65, 0.88] | 7 studies · 2879 participants | Moderate Downgraded: risk of bias, indirectness |
Overall survival (OS)median Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy | HR 0.89 [0.81, 0.98] | 8 studies · 13547 participants | Moderate Downgraded: risk of bias, indirectness |
Febrile neutropenia Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy | OR 0.55 [0.47, 0.64] | 5 studies · 8086 participants | Moderate Downgraded: risk of bias, inconsistency |
Diarrhoea Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy | OR 2.46 [2.01, 3.01] | 8 studies · 11207 participants | Moderate Downgraded: risk of bias, inconsistency |
Hand‐foot syndrome Capecitabine‐containing regimens vs non‐capecitabine‐containing regimens or no chemotherapy | OR 13.6 [10.65, 17.37] | 8 studies · 11207 participants | Moderate Downgraded: risk of bias, inconsistency |